[VIRTUAL] Safety and feasibility of rhenium-186 nanoliposome (186RNL) in recurrent glioma: The ReSPECT phase 1 trial. (ASCO 2021) - Apr 28, 2021 - Abstract #2061; Pres time: Jun 4, 2021; 08:00 AM - 11:00 AM; P1/2 | "186RNL administered by CED to patients with recurrent glioma results in a much higher absorbed dose of radiation to the tumor compared to EBRT without significant toxicity . The recommended Phase 2 dose is 22.3 mCi in 8.8 mL of infusate."
Clinical • P1 data • Brain Cancer • Glioma • Oncology • Solid Tumor
|
|
Andrew J. Brenner; Ande Bao; William Phillips; Gregory Stein; Vibhudutta Awasthi; Toral R. Patel; Jeffrey Weinberg; John Floyd
|